Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2021 edition).
10.3760/cma.j.cn112152-20210811-00605
- VernacularTitle:非肌层浸润性膀胱癌膀胱灌注治疗专家共识(2021版)
- Collective Name:Urological Chinese Oncology Group
- Publication Type:Journal Article
- Keywords:
Bladder neoplasms;
Expert consensus;
Intravesical therapy
- MeSH:
Adjuvants, Immunologic/therapeutic use*;
Administration, Intravesical;
Consensus;
Humans;
Neoplasm Invasiveness;
Neoplasm Recurrence, Local/drug therapy*;
Urinary Bladder Neoplasms/drug therapy*
- From:
Chinese Journal of Oncology
2021;43(10):1027-1033
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer is one of the common malignant tumors in China, with 75% of bladder cancer being non-muscle invasion with a high recurrence rate after surgery. Intravesical therapy is an useful methods to either directly kill tumor cells by infusing cytotoxic drugs into the bladder or directly or indirectly induce local immune responses of the body through infusing immune agents, such as bacillus calmette guerin, and thus reduce the risk of tumor recurrence and progression. In 2019, the Urological Chinese Oncology Group issued the "Expert consensus on intravesical therapy on non-muscle invasive bladder cancer" . Recently, great progress in the clinical diagnosis and treatment of non-muscle invasive bladder cancer has been achieved domestically and abroad, including the risk assessment of non-muscle invasive bladder cancer, the therapeutic choice of intravesical drugs, the adverse reactions and treatment experience of intravesical therapy, and clinical research on new types of intravesical drugs. This consensus is made according to domestic and overseas evidence-based medicine in combination with current clinical practice and experience of intravesical therapy for non-muscle invasive bladder cancer in China. It is an update of the 2019 expert consensus, with the wish to provide a guidance for domestic clinical standardized intravesical therapy for non-muscle invasive bladder cancer.
